奥氮平治疗首发精神分裂症疗效观察
奥氮平；首发精神分裂症；疗效,,奥氮平；首发精神分裂症；疗效,【摘要】,【关键词】,1对象与方法,2结果,3讨论,参考文献
【摘要】 目的 评价奥氮平治疗首发精神分裂症的疗效与安全性。 方法 对36例住院首发精神分裂症患者给予奥氮平治疗，起始剂量5mg·d-1，1w内根据病情调整至治疗剂量10～25mg·d-1，平均剂量16.33±5.24mg·d-1。疗程8w。分别于治疗前及治疗第2、4、8w末采用潘氏量表评定临床疗效，副反应量表评定不良反应。 结果 治疗2、4、8w末潘氏量表评分与治疗前比较差异有极显著性(P均<0.01)。其中痊愈15例(41.7%)，显进12例(33.3%)，进步6例(16.7%)，无效3例(8.3%)，总有效率91.7%。不良反应轻微，无明显心血管系统不良反应。 结论 奥氮平治疗首发精神分裂症安全有效，值得临床推广应用。【关键词】 奥氮平；首发精神分裂症；疗效
The efficacy of olanzapine in the treatment of firstepisode schizophrenia
Dong Songyu ,Gao Huan,Feng Zheng
(Kangning hospital ,Shenzhen 518020,Guangdong,China)
【Abstract】 Objective To evaluate the efficacy and safety of olanzapine in the treatment of firstepisode schizophrenia. Methods 36 hospitalized firstepisode schizophrenics were treated with olanzapine, initial dosage was 5mg/d raised to 10~25mg/d within one week and mean dosage 16.33±5.24mg/d for 8 weeks. Efficacies and side effects were assessed with the Positive and Negative Symptoms Scale(PANSS) and Treatment Emergent Symptom Scale(TESS) before treatment and at the ends of week 2,4 and 8 during treatment, respectively. Results The PANSS scores at the 3 timepoints during treatment all were significant different from pretreatment( all P<0.01).Of the 36 patients,15(41.7%) were recovery,12(33.3%) significant improvement,6(16.7%) improvement and 3(8.3) ineffective, the total effective rate was 91.7%. The side effects were milder, it had no obvious side effects of cardiovascular system. Conclusion Olanzapine is a safe and effective in the treatment of firstepisode schizophrenia, and deserve to be clinically popularized. ......
您现在查看是摘要页，全文长 5338 字符。